STAT+: Pharmalittle: Sanofi and Glaxo tout positive Covid-19 vaccine results; Pfizer exec warns IP waiver will cause materials shortage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was enjoyable, because that startling routine of deadlines and meetings and what-not has now returned. But you knew this was coming, yes? Avoiding the future is a difficult thing. So please join us as we hoist our ritualistic cup of stimulation and attack the ever-growing to-do list. Meanwhile, here are some tidbits to get you started. Hope you conquer the world today, and do keep us in mind if you hear anything interesting. …
Sanofi (SNY) and GlaxoSmithKline (GSK) announced positive results from a Phase 2 clinical trial of their joint Covid-19 vaccine, saying it generated strong levels of neutralizing antibodies in recipients across all ages studied, and that a large international Phase 3 trial will begin in coming weeks, STAT says. The duo is far behind in the effort to produce a vaccine and lock down markets for their product, having suffered a setback in a Phase 1/2 trial last year. But with global vaccine supplies falling short, they still believe there is a place for their shot.
